PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation

Arthritis and Rheumatism

Volumn 44, Issue 12, 2001, Pages 2841-2850

  Fazzini, Fausto ^a   Peri, Giuseppe ^b   Doni, Andrea ^b   Dell'Antonio, Giacomo ^a   Dal Cin, Elena ^a   Bozzolo, Enrica ^a   D'Auria, Francesca ^a   Praderio, Luisa ^a   Ciboddo, Gianfranco ^a   Sabbadini, Maria Grazia ^a   Manfredi, Angelo A ^a   Mantovani, Alberto ^b   Querini, Patrizia Rovere ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c San Raf faele Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENTRAXIN; PENTRAXIN 3; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAPILLARY; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM; VASCULITIS; WEGENER GRANULOMATOSIS;

ACUTE DISEASE; ACUTE-PHASE REACTION; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHILD; CHURG-STRAUSS SYNDROME; CREST SYNDROME; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; WEGENER GRANULOMATOSIS;

EID: 0035677836     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6     Document Type: Article

References (41)

1. Pathogenic mechanisms of vessel damage in vasculitis syndromes
2. Immunopathogenesis of vasculitis
3. Vascularites systémiques: Généralités, classification, mécanismes
4. Serum cytokine changes in systemic vasculitis
5. Cytokine regulation of endothelial cell function: From molecular level to the bedside
6. Pathogenesis of Wegener's granulomatosis
7. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1
8. Relapses in patients with a systemic vasculitis
9. A review on the biological properties of C-reactive protein
10. The acute phase response
11. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein
12. Structure and function of the pentraxins
13. Interleukin-1 inducible genes in endothelial cells: Cloning of a new gene related to C-reactive protein and serum amyloid P component
14. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins
15. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes
16. Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins
17. What is new with anti-neutrophil cytoplasmic antibodies: Diagnostic, pathogenetic and therapeutic implications
18. Pathogenesis of ANCA-associated systemic vasculitis
19. Regulation of inflammatory vascular damage
20. Leukocytoclastic vasculitis
21. The importance of being eaten
22. Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro
23. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity
24. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity
25. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen presenting dendritic cells
26. Nomenclature of systemic vasculitides: Proposal of an international consensus conference
27. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)
28. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis
29. Birmingham vasculitis activity score (BVAS) in systemic vasculitis
30. The 1982 revised criteria for the classification of systemic lupus erythematosus
31. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
32. Derivation of the SLEDAI: A disease activity index for lupus patients
33. Expression of the long pentraxin PTX3 by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan
34. PTX3, a prototypicalal long pentraxin, is an early indicator of acute myocardial infarction in humans
35. Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis: Relationship to disease activity and relevance during followup
36. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: Relation to inflammatory cytokines and modulation by dexamethasone and rolipram
37. Inducible expression of the long pentraxin PTX3 in the central nervous system
38. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)
39. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients
40. Multimer formation and ligand recognition by the long pentraxin PTX3: Similarities and differences with the short pentraxins C reactive protein and serum amyloid P component
41. Remnants of suicidal cells fostering systemic autoaggression: Apoptosis in the origin and maintenance of autoimmunity